DiCE Molecules
Chen Wang is a seasoned professional in statistical programming and immunological research, currently serving as Senior Manager of Statistical Programming at DICE Therapeutics since 2023. Prior experience includes a role as Statistical Programmer at Gilead from 2014 to 2023, and part-time Researcher at Stanford University between 2011 and 2014, specializing in the analysis of antibodies and the human adaptive immune system. Chen Wang's earlier work includes two postdoctoral fellowships at Genentech and UCSF focused on immune cell regulation and T lymphocyte activation, as well as a research assistantship at Albert Einstein College of Medicine examining non-coding RNAs. Chen Wang holds a Ph.D. in Molecular Biology from Albert Einstein College of Medicine, along with an M.S. and B.S. in Molecular Biology and Biology, respectively, from the University of Science and Technology of China.
DiCE Molecules
DiCE Molecules designs and develops innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, they are developing oral alternatives to medicines currently limited to injectable forms.